Fairmount Funds Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $74.5M | Buy |
3,711,444
+508,646
| +16% | +$10.2M | 9.65% | 3 |
|
|
2025
Q1 | $63M | Hold |
3,202,798
| – | – | 9.78% | 4 |
|
|
2024
Q4 | $72.1M | Hold |
3,202,798
| – | – | 7.16% | 6 |
|
|
2024
Q3 | $81.8M | Hold |
3,202,798
| – | – | 6.63% | 5 |
|
|
2024
Q2 | $74.8M | Hold |
3,202,798
| – | – | 8.46% | 5 |
|
|
2024
Q1 | $56.3M | Buy |
3,202,798
+1,071,429
| +50% | +$18.8M | 6.14% | 6 |
|
|
2023
Q4 | $29.5M | Hold |
2,131,369
| – | – | 3.12% | 9 |
|
|
2023
Q3 | $29.1M | Buy |
2,131,369
+6,744
| +0.3% | +$92.1K | 3.5% | 10 |
|
|
2023
Q2 | $43.4M | Buy |
2,124,625
+199,687
| +10% | +$4.08M | 6.11% | 4 |
|
|
2023
Q1 | $42.2M | Buy |
1,924,938
+1,767,105
| +1,120% | +$38.7M | 7.25% | 5 |
|
|
2022
Q4 | $2.58M | Buy |
+157,833
| New | +$2.58M | 0.41% | 16 |
|